Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted during the month of June 2025. The specific transaction occurred on June 18, 2025, executed through the corporate stockbroker Merrill Lynch International. The filing serves to disclose the purchase of ordinary shares as part of the Company's existing buyback programme.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction on June 18, 2025, include:
- Shares Purchased: 468,255 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,444.00p; highest price paid was 1,469.50p.
- Average Price: Volume-weighted average price paid was 1,454.83p.
- Trading Venue: All shares were purchased on the London Stock Exchange (XLON).
- Treasury Holdings: Following this purchase, the Company holds 222,325,965 ordinary shares in treasury.
- Shares in Issue: 4,092,975,624 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.43% of the total voting rights.
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Since the commencement of the current buyback agreement on June 4, 2025, the Company has purchased an aggregate of 4,191,582 ordinary shares. The June 18 transaction represents a continuation of this programme. There are no other material changes to the Company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook regarding future performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q1 Results for 2025. No unusual items or contingencies are reported in this document.
Investor Verification Checklist
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (stated as 4,191,582).
- Confirm the updated percentage of voting rights held in treasury (stated as 5.43%).
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on forward-looking statements.
- Check the total number of ordinary shares in issue excluding treasury shares (stated as 4,092,975,624).